Goodwill and Intangible Assets, Net

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows:



Balance at December 31, 2015	$	165,169
Foreign currency translation adjustments	(5,376		)
Balance at September 30, 2016	$	159,793

No goodwill or accumulated impairment losses existed as of September 30, 2016 and December 31, 2015.

Intangible assets consist of the following at September 30, 2016:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	15.3	$	170,520	$	(26,596	)	$	143,924
Customer relationships	6.5	10,700		(4,189		)	6,511
Trademarks	9.3	6,800		(1,598		)	5,202
Covenant not to compete	2.0	395		(312		)	83
In-process research and development		82,861		—			82,861
Total		$	271,276	$	(32,695	)	$	238,581

Intangible assets consist of the following at December 31, 2015:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	$	157,411	$	(17,775	)	$	139,636
Customer relationships	10,700		(2,739		)	7,961
Trademarks	6,800		(1,018		)	5,782
Covenant not to compete	384		(160		)	224
In-process research and development	93,932		—			93,932
Total	$	269,227	$	(21,692	)	$	247,535

The balance of in-process research and development as of September 30, 2016 primarily includes the in-process research and development acquired in the Company's Oxitec acquisition and amortization will begin once certain regulatory approvals have been obtained.

Amortization expense was $3,651 and $2,857 for the three months ended September 30, 2016 and 2015, respectively, and $10,888 and $6,434 for the nine months ended September 30, 2016 and 2015, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details